Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 11, 1997, Pages 2433-2438

  Vanhove, Geertrui F ^a   Gries, Jean Michel ^b   Verotta, Davide ^b   Sheiner, Lewis B ^b,c   Coombs, Robert ^d   Collier, Ann C ^d   Blaschke, Terrence F ^a,e  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STIMULUS RESPONSE;

EID: 0030690998     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.11.2433     Document Type: Article

References (15)

1. Beal, S. L., and L. B. Sheiner. 1991. NONMEM user's guide. NONMEM Project Group, University of California at San Francisco, San Francisco, Calif.
2. + T-cell determinations in persons with human immunodeficiency virus infection. Morbid. Mortal. Weekly Rep. 41(RR-8):1-17.
3. Collier, A. C., R. W. Coombs, D. A. Schoenfeld, R. Bassett, et al. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N. Engl. J. Med. 334:1011-1017.
4. Craig, J. C., I. B. Duncan, L. Whittaker, and N. A. Roberts. 1993. Antiviral synergy between inhibitors of HIV protease and reverse transcriptase. Antiviral Chem. Chemother. 4:161-166.
5. Fiscus, S. A., V. DeGruttola, P. Gupta, D. A. Katzenstein, W. A. Meyer, M. L. LoFaro, M. Katzman, M. V. Ragni, P. S. Reichelderfer, and R. W. Coombs. 1995. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multi-center clinical trial. J. Infect. Dis. 171:305-311.
6. Gries, J. M., D. Verotta, and L. B. Sheiner. Unpublished data.
7. Hastie, T. J., and R. J. Tibishirani. 1990. Generalized additive models. Monographs on statistics an applied probability 43. Chapman & Hall, New York, N.Y.
8. Hollinger, F. B., J. W. Bremer, L. E. Myers, J. W. M. Gold, L. McQuay, and The NIH/NIAID/DAIDS/ACTG Virology Laboratories. 1992. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trial Group. J. Clin. Microbiol. 30:1787-1794.
9. Johnson, V. A., D. P. Merrill, T. C. Chou, and M. S. Hirsch. 1992. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-alpha against zidovudine-sensitive or -resistant HIV-1 in vitro. J. Infect. Dis. 166:1143-1146.
10. Pachl, C., J. A. Todd, D. G. Kern, P. J. Sheridan, S. J. Fong, M. Stempien, B. Hoo, D. Besemer, T. Yeghiazarian, B. Irvine et al. 1995. Rapid and precise quantification of HIV-1 RNA in plasma using branched DNA signal amplification assay. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 8:446-454.
11. Sale, M., L. B. Sheiner, P. Volberding, and T. Blaschke. 1993. Zidovudine response relationships in early human immunodeficiency virus infection. Clin. Pharmacol. Ther. 54:556-566.
12. + T-cell counts in HIV-infected patients. Ann. Intern. Med. 124:1039-1050.
13. Stretcher, B. N., A. J. Pesce, P. T. Frame, K. A. Greenberg, and D. S. Stein. 1994. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 8:763-769.
14. Stretcher, B. N., A. J. Pesce, J. A. Murray, P. E. Hurtubise, W. H. Vine, and P. T. Frame. 1991. Concentrations of phosphorylated zidovudine in patient leukocytes do not correlate with ZDV dose or plasma concentrations. Ther. Drug Monit. 13:325-331.
15. Verhove, G. F., H. Kastrissios, J.-M. Gries, D. Verotta, K. Park, A. C. Collier, K. Squires, L. B. Sheiner, and T. F. Blaschke. 1997. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrobial Agents Chemother. 41:2428-2432.